What is Zacks Research’s Estimate for IRWD FY2026 Earnings?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Research analysts at Zacks Research raised their FY2026 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a report issued on Wednesday, January 8th. Zacks Research analyst R. Department now expects that the biotechnology company will earn $0.44 per share for the year, up from their previous forecast of $0.43. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.08 per share.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company had revenue of $91.60 million during the quarter, compared to analysts’ expectations of $91.22 million. During the same quarter in the previous year, the company earned $0.12 EPS. The business’s quarterly revenue was down 19.4% compared to the same quarter last year.

Separately, StockNews.com lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Ironwood Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $10.40.

Ironwood Pharmaceuticals Trading Down 3.2 %

Ironwood Pharmaceuticals stock opened at $3.65 on Monday. Ironwood Pharmaceuticals has a 12-month low of $3.06 and a 12-month high of $15.70. The firm has a market capitalization of $584.10 million, a price-to-earnings ratio of -121.67 and a beta of 0.34. The firm has a 50 day moving average of $4.03 and a 200 day moving average of $4.69.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the sale, the chief financial officer now owns 309,572 shares in the company, valued at $1,263,053.76. The trade was a 3.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 12.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of IRWD. Armistice Capital LLC lifted its position in Ironwood Pharmaceuticals by 44.4% during the second quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company’s stock valued at $50,856,000 after purchasing an additional 2,400,000 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Ironwood Pharmaceuticals by 26.6% in the 3rd quarter. Pacer Advisors Inc. now owns 11,279,822 shares of the biotechnology company’s stock valued at $46,473,000 after acquiring an additional 2,372,183 shares during the last quarter. Renaissance Technologies LLC grew its position in Ironwood Pharmaceuticals by 20.7% in the second quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company’s stock worth $55,889,000 after acquiring an additional 1,472,097 shares in the last quarter. Stonepine Capital Management LLC increased its stake in Ironwood Pharmaceuticals by 1,982.8% during the third quarter. Stonepine Capital Management LLC now owns 1,000,000 shares of the biotechnology company’s stock worth $4,120,000 after acquiring an additional 951,988 shares during the last quarter. Finally, State Street Corp raised its position in Ironwood Pharmaceuticals by 7.3% during the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock valued at $40,870,000 after purchasing an additional 677,024 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.